Cabotegravir

• Impact of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis persistence and coverage in men who have sex with men in Fran… Ended
  2024-510678-25-00 Phase III/IV 1 country Inserm
• Long Acting Cabotegravir plus Rilpivirine in People Living with HIV-1 (PLHIV) Aged ≥ 60 Years for 96 weeks. Ended
  2022-502882-53-00 Phase IV 1 country Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
• PH 3b, CAB + RPV in people with suboptimal response to oral ART (CROWN) Ended
  2024-515070-28-00 Phase III 5 countries Viiv Healthcare UK Limited
• A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim… Ended
  2023-503893-19-00 Phase III 4 countries Viiv Healthcare UK Limited
• Implementation of Out-of-HOspital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infec… Ended
  2023-503963-41-00 Phase IV 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Ended
  2024-515487-31-00 Phase IV 5 countries Stichting Radboud universitair medisch centrum
• Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA Ended
  2024-516028-33-01 Phase III 1 country Inst Medecine Epidemiologie Appliquee

Showing 1–7 of 7 trials